LeonaBio

Biotechnology ResearchWashington, United States51-200 Employees

LeonaBio is a clinical-stage biotechnology company focused on developing novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and ALS. It is headquartered in Bothell, Washington, and employs 51 to 200 people. The company holds a license to a Phase 3 Lasofoxifene program, a selective estrogen receptor modulator, pursuing a registrational study in ESR1-mutated metastatic ER-positive, HER2-negative breast cancer, with enrollment expected to complete in 4Q26 and topline data anticipated in 2H27. It also plans a Phase 2 proof-of-concept study of ATH-1105 in ALS in the second half of 2026. LeonaBio has expanded its governance through new board appointments and engages with the scientific community through presentations and industry conferences in 2026.

Sign up for free to view info

Email Format Employee directory